Bree Foster, PhD
Bree Foster is a science writer at Drug Discovery News with over 2 years of experience at Technology Networks, Drug Discovery News, and other scientific marketing agencies. She holds a PhD in comparative and functional genomics from the University of Liverpool and enjoys crafting compelling stories for science.
Articles by Bree Foster, PhD
| 4 min read
The HDAC inhibitor givinostat has received regulatory approval in the US, EU, and UK for patients six years and older.
| 7 min read
Men have long lacked reversible contraceptives, but new hormonal and non-hormonal methods in development could finally give them control over family planning.
| 8 min read
Jo Varshney explains how human-relevant models and mechanistic simulations are transforming early-stage drug discovery and development.
| 3 min read
From multiomic diagnostics to quantum computing, leading experts share the untapped opportunities that could reshape the future of therapeutics.
| 6 min read
Researchers can now train AI models on over 5 million protein-ligand structures to predict drug potency faster and more accurately than ever.
| 6 min read
AI is changing how experiments are designed, executed, and interpreted in early-stage drug discovery.
| 5 min read
Computational models are reshaping how therapies are discovered, tested, and optimized.
| 5 min read
Regulatory science is increasingly relying on modeling, simulation, and AI tools to accelerate drug development while maintaining safety and efficacy.
| 3 min read
At analytica USA 2025, discover how AI is transforming labs with automated molecule identification, natural language data access, and intelligent workflows.
| 4 min read
Short-acting psychedelics like bretisilocin could offer rapid, lasting relief for patients with major depressive disorder.
| 3 min read
By combining synthetic biology, computational design, and novel RNA formats, these therapies adapt in real time to disease signals, enabling previously impossible treatments.
| 3 min read
After decades of stalled innovation, a new oral antibiotic could now combat both everyday infections and urgent public health threats.
